Clinical Trials Browser

Withdrawn × Brain Neoplasms × pembrolizumab × Clear all

NCT07011849 2025-08-13

Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

Phase 2 Withdrawn

CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell

NCT05255666 2023-07-11

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Phase 2 Withdrawn

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT04512261 2022-07-01

TOPAZ

Phase 1/2 Withdrawn

Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases